Issue 5/2016
Content (9 Articles)
Current Opinion
Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere?
Sean G. Kelly, Amesika N. Nyaku, Babafemi O. Taiwo
Leading Article
Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection
Denise C. Hsu, Irini Sereti
Therapy in Practice
The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions
Paolo Curatolo, Marit Bjørnvold, Patricia E. Dill, José Carlos Ferreira, Martha Feucht, Christoph Hertzberg, Anna Jansen, Sergiusz Jóźwiak, J. Christopher Kingswood, Katarzyna Kotulska, Alfons Macaya, Romina Moavero, Rima Nabbout, Bernard A. Zonnenberg
Review Article
Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent
George G. Zhanel, Doris Cheung, Heather Adam, Sheryl Zelenitsky, Alyssa Golden, Frank Schweizer, Bala Gorityala, Philippe R. S. Lagacé-Wiens, Andrew Walkty, Alfred S. Gin, Daryl J. Hoban, James A. Karlowsky
Review Article
Antipsychotic Management of Schizoaffective Disorder: A Review
Jean-Pierre Lindenmayer, Amandeep Kaur
Adis Drug Evaluation
Cobimetinib Plus Vemurafenib: A Review in BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma
Gillian M. Keating
Letter to the Editor
Comment on: “Therapies to Preserve β-Cell Function in Type 1 Diabetes”
Devi Dayal
Letter to the Editor
Author’s Reply to Dayal: “Therapies to Preserve β-Cell Function in Type 1 Diabetes”
Johnny Ludvigsson